NOVKAN — Novakand Pharma AB Income Statement
0.000.00%
Last trade - 00:00- SEK6.18m
- -SEK9.89m
Annual income statement for Novakand Pharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0 | 0 | 0 | 0 | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 45.3 | 51.9 | 65 | 46.2 | 47.6 |
| Operating Profit | -45.3 | -51.9 | -65 | -46.2 | -47.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -45.7 | -52.5 | -64.9 | -44.6 | -47.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -45.7 | -52.5 | -64.9 | -44.6 | -47.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -45.7 | -52.5 | -64.9 | -44.6 | -47.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -45.7 | -52.5 | -64.9 | -44.6 | -47.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.706 | -0.887 | -0.765 | -0.386 | -0.241 |
| Dividends per Share |